Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Shares of clinical-stage biotech Ocugen (OCGN 11.50%) climbed as high as 14.2% on Thursday, to $1.29, shortly before noon.
Ocugen focuses on gene and cell therapies and vaccines to treat retinal diseases, infectious diseases, and orthopedic conditions. The stock is a meme favorite, listed at No. 79 on the Robinhood Top 100 list, and as such has been volatile.
It’s possible, with 18.87% of the float sold short, some traders could be attempting a short squeeze. The company didn’t have any announcements on Wednesday or Thursday. It’s down more than 72% so far this year and is a lot closer to its 52-week low of $1.09 than its 52-week high of $5.06.
Ocugen doesn’t have any marketed products and no revenue yet. In the third quarter, the company reported an earnings per share (EPS) loss of $0.10, compared to an EPS loss of $0.05 in the third quarter of 2021.
It reported $101.6 million in cash as of Sept. 30, enough to fund operations into the fourth quarter of 2023. That’s not a big window to turn things around.
The healthcare company has had some positive news lately, though. On Dec. 16, three days after its executives rang the closing bell for the Nasdaq Exchange, Ocugen got approval from the Food and Drug Administration for the design of the company’s Phase 3 study of regenerative cell therapy NeoCart. The therapy is being tested to repair lesions in the knee cartilage of adults.
The concern for investors, however, is that with so little cash, the biotech presents a great deal of risk since it will likely need more funding to bring any of its therapies to market.
Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.
Making the world smarter, happier, and richer.
Market data powered by Xignite.
